Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M. Hussain"'
Publikováno v:
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 31(10)
The natural history of benign enlargement of the prostate is variable and ranges from mild symptoms to chronic retention and renal failure. In this study, the outcomes of patients with urinary retention alone were compared with those of chronic reten
Publikováno v:
European Urology. 79:S958
Publikováno v:
African Journal of Urology; Vol 22, No 2 (2016); 96-100
African Journal of Urology, Vol 22, Iss 2, Pp 96-100 (2016)
African Journal of Urology, Vol 22, Iss 2, Pp 96-100 (2016)
Objective: To determine the role of the lower pole infundibular parameters as predictors of stone clearance following extracorporeal shock wave lithotripsy (ESWL). Subjects and methods: Between March 2001 and February 2004, 243 renal units in 239 pat
Autor:
Kalathil K Sureshkumar, Carlos A Vivas, Ngoc Thai, Kusum Tom, George Parris, Sabiha M Hussain, Tina Y. Ko, Akhtar Khan, Katherine M. Jasnosz, Richard J. Marcus
Publikováno v:
Clinical Nephrology. 77:246-253
Antibody-mediated rejection (AMR) following renal transplantation is less responsive to conventional anti-rejection therapies. Plasmapheresis (PP), intravenous immunoglobulin (IVIg), rabbit antithymocyte globulin (rATG) and rituximab deplete immature
Autor:
Kalathil K Sureshkumar, Barbara J Carpenter, Sabiha M Hussain, Stephen Sandroni, Richard J. Marcus
Publikováno v:
Expert Opinion on Pharmacotherapy. 8:913-921
Antibody-mediated rejection (AMR) accounts for 20 – 30% of all acute rejection episodes following renal transplantation. AMR is generally less responsive to conventional anti-rejection therapy, resulting in poor allograft survival. Introduction of
Autor:
Kalathil K Sureshkumar, Janice G. Nigos, Richard J. Marcus, Parineesha Nath, Sabiha M Hussain, Tina Y. Ko, Swati Arora
Publikováno v:
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 10(6)
OBJECTIVES Antibody-mediated rejection after kidney transplant is less responsive to conventional antirejection therapies. The proteasome inhibitor bortezomib has activity against mature plasma cells that produce damaging donor-specific antibodies. W
Publikováno v:
Transplantation. 93(8)
BACKGROUND Over last several years, alemtuzumab induction has been increasingly used in kidney transplantation especially in patients maintained on steroid-free immunosuppression. It is unclear which induction agent is associated with better graft an
Publikováno v:
European Urology Supplements. 8:327